|Home | About | Journals | Submit | Contact Us | Français|
To evaluate the role of oxidative stress in prostate cancer risk, we analyzed serum levels of protein carbonyl groups in 1808 prostate cancer cases and 1805 controls, nested in the Prostate Cancer Prevention Trial, a randomized, placebo-control trial that found finasteride decreased prostate cancer risk. There were no significant differences in protein carbonyl levels in baseline samples between those later diagnosed with prostate cancer and those without at the end of study biopsy. Adjusted ORs and 95% CIs for the 4th quartile of protein carbonyl level for the combined, placebo and finasteride arms were 1.03 (95% CI 0.85–1.24), 0.88 (95% CI 0.69–1.12) and 1.27 (95% CI 0.94–1.71), respectively. There were no significant associations between carbonyl level and risk when analyzing high- and low-grade disease separately, nor did finasteride impact protein oxidation levels. The results of this large nested case-control study do not support the hypothesis that oxidative stress, at least as measured by protein carbonyl level, plays a role in prostate cancer.
Increases in the generation of reactive oxygen species (ROS) and decreases in antioxidant enzyme activities with aging have been reported in the prostate1;2, and are also observed in age-related disorders such as atherosclerosis, Alzheimer’s disease, and cataracts.3 Several studies have demonstrated that proteins are a target for reactive oxidants in cells and that oxidized proteins accumulate during aging, oxidative stress and in some pathological conditions.4 However, only limited a number of studies have actually evaluated oxidative damage in relation to exposures thought to increase ROS or have assessed its relationship with prostate carcinogenesis3. In this nested case-control study, we measured protein carbonyls, a marker for oxidative damage, in serum samples from men who participated in the Prostate Cancer Prevention Trial (PCPT) and had received either finasteride or placebo treatment from 1993–2003.5 The goal of this investigation was to determine whether baseline levels of serum levels of oxidized proteins are associated with an increased risk of prostate cancer or high-grade disease. We also examined associations between serum protein carbonyl levels and other factors thought to be associated with oxidative stress levels.
Data and biospecimens used in this study came from the PCPT, a large, phase III, double-blind, placebo-controlled trial that tested whether finasteride could reduce the period prevalence of prostate cancer during the 7-year intervention. Details regarding study design and population characteristics have been described previously.5 Briefly, a total of 18,880 men ages 55 years or older with a normal digital rectal examination (DRE), a prostate-specific antigen (PSA) level of ≤3 ng/mL, and no prior history of prostate cancer, severe benign prostate hyperplasia, or orther clinically significant diseases, were randomized to receive finasteride (5 mg/day) or placebo. Participants underwent DRE and PSA test annually, and a prostate biopsy was recommended for participants with an abnormal DRE or a PSA of ≥4.0 ng/mL. The PSA level prompting a biopsy recommendation in the finasteride group was adjusted so as to result in a similar number of biopsy recommendations in both study groups. After seven years on-study, all men with PSA values consistently ≤4.0 ng/mL and non-suspicious DREs who were not previously diagnosed with prostate cancer were offered an end-of-study biopsy. All biopsies were performed under transrectal ultrasonographic guidance and included a minimum of six cores. All prostate biopsies were reviewed by both the pathologist at the local study site and at a central PCPT pathology laboratory to confirm the diagnosis of adenocarcinoma. Discordant pathology diagnoses were reviewed by a referee pathologist, and concordance was achieved in all cases. Clinical stage was assigned locally and the Gleason scoring system was used centrally to grade the tumor. Low-grade prostate cancer was defined as tumors with Gleason score <7 and high-grade prostate cancer with Gleason score ≥7. In this study, we used a nested case-control design to evaluate whether higher levels of serum oxidized proteins were associated with higher overall prostate cancer risk and high-grade disease and whether the effects of finasteride on prostate cancer risk differed between men with high and low levels of serum oxidized protein. Cases were defined as men with biopsy-proven prostate cancer and controls were biopsy-negative, both having available serum samples for oxidized protein analysis. Controls were frequency matched to cases on age in five-year increments, PCPT treatment arm (finasteride vs. placebo) and positive family history (first degree relative with prostate cancer). Controls were oversampled to include all non-Whites to increase power for analyses by race/ethnicity. The final sample size for this study was 1808 cases and 1805 controls.
Following each PCPT participant’s informed consent and enrollment, data on socio-demographic characteristics, including age, race, education, physical activity, smoking, fruit intake, vegetable intake, treatment arm (finasteride/placebo), and family history of prostate cancer were collected. Height and weight were measured at the baseline clinic visit, and weight was measured annually thereafter. Body mass index (BMI) was calculated as weight (kg) divided by height (m2) and categorized as <25 (normal), 25–30 (overweight) and ≥30 (obese). A food frequency questionnaire was administered at the participant’s first annual visit and was completed by 88% of the participant population, from which daily fruit and vegetable intakes were calculated.
Blood samples were collected into vacutainers without anticoagulant but with a gel to separate serum from clot from all cases and controls three months before randomization and annually. Samples were centrifuged after 30–60 min at room temperature and serum stored at −70°C. Detailed procedures for blood collection, processing and storage have been described previously.6
The levels of serum protein carbonyl groups were assessed using a noncompetitive ELISA, as previously described.7 Briefly, the oxidized protein standard was prepared by incubation of bovine serum albumin (BSA) with 0.73 M H2O2 and 0.42 mM Fe2+ for 1 h at 37°C and carbonyl content measured spectrophotometrically.8 Total protein concentration in the serum was measured using a Bicinchoninic Acid Kit (Sigma) and the samples were diluted with phosphate buffered saline to a final protein concentration of 4 mg/ml. After derivatization with DNPH, the plate was coated with 200 μl of sample (1 μg) and incubated overnight at 4°C in the dark. Biotinylated primary anti-DNP antibody (Molecular Probes) was followed by the addition of the streptavidin-biotynylated horseradish peroxidase conjugate (Amersham). Color was developed by adding the tetramethyl benzidine (TMB) liquid substrate system (Sigma) and the reaction was stopped with H2SO4. The absorbance was measured with a microplate reader at 450 nm. Serum protein carbonyl concentration was expressed as nmol carbonyl/ml serum. Each sample was analyzed in duplicate. To account for plate variation, values were adjusted for a plate-specific control. Two pooled serum samples were used for additional quality control. These samples were blinded and interspersed among the study participant samples. The coefficient of variation for pool 1 (N=49) was 16.3% for QC Pool 1 and 15.2% for pool 2 (N= 53).
Characteristics of cases and controls were compared using chi-square test for categorical variables and t-test for continuous variables. Serum concentrations of protein carbonyls were categorized into quartiles based on the distribution in the controls. We calculated ORs and 95% confidence intervals (95% CI) for prostate cancer risk using multiple logistic regression analysis and polychotomous logistic regression models to calculate ORs for low-grade and high-grade prostate cancer compared to controls. These analyses were adjusted for age (continuous), race (white versus nonwhite), education (high school degree or less, some college or college degree, and advanced degree), physical activity (moderate or active versus sedentary or light), smoking (nonsmoker, current and past), daily fruit intake (<1serving, 1 to <2 servings and 2+ servings), daily vegetable intake (<1serving, 1 to <2 servings, 2 to <3 servings and 3+ servings) and treatment arm (finasteride versus placebo), and family history of prostate cancer in first-degree relatives (yes versus no). We also conducted stratified analyses to assess the interaction between oxidized protein concentration and finasteride use. All P values were 2-sided and were considered statistically significant at P < 0.05. All analyses were performed using SAS (version 9.0, Cary, NC).
The characteristics of the cases and controls are shown in Table 1. Due to the sampling scheme, 93% of cases and 79% of controls were Caucasian. There were no significant differences between cases and controls according to age, BMI, smoking status, education, alcohol consumption, physical activity and daily vegetable and fruit intake. The mean level of serum protein carbonyls among cases (19.83±4.39 nmol/mL) and controls (19.81±3.74 nmol/mL) was also similar. When we compared protein carbonyl levels in cases and controls stratified by variables that are thought to be associated with oxidative stress, no significant associations were found in either cases or controls (Table 2). We also measured serum protein carbonyl levels in the second year of intervention, but did not observe any differences compared to baseline by treatment arm (data not shown).
There was no significant association between serum protein carbonyl levels and risk of prostate cancer in either the placebo and finasteride arms separately or in the entire study population (Table 3). Adjusted ORs and 95% CIs for the 4th quartile of protein carbonyl level for the combined, placebo and finasteride arms were 1.03 (95% CI 0.85–1.24), 0.88 (95% CI 0.69–1.12) and 1.27 (95% CI 0.94–1.71), respectively. Although the association was stronger in the finasteride arm, it was not statistically significant (Table 3). Results were similar when we restricted our analysis to White participants only (Data not shown).
When examining associations between oxidized protein levels and prostate cancer grade, no statistically significant relationships were observed (Table 4). ORs and 95% CIs for high-grade cancer within the 4th quartile of protein carbonyl level for the combined, placebo and finasteride arms were 1.02 (95% CI 0.77–1.36), 0.84 (95% CI 0.56–1.27) and 1.25 (95% CI 0.83–1.87), respectively (Table 4). Results were similar when analyses were restricted to White participants only (data not shown).
There were no significant associations between prostate cancer risk or its aggressiveness and serum levels of oxidized protein as measured by protein carbonyls in this large nested case-control study. While the cancer risk associated with the highest oxidized protein levels was slightly elevated in the finasteride arm, the association did not reach statistical significance. Finasteride did not appear to impact serum protein carbonyl levels when comparing baseline measurements to those obtained after 2 yrs on finasteride. There were also no significant associations between factors considered to be associated with increased oxidative stress and oxidized protein levels.
In our prior large study of breast cancer, protein oxidation, defined as high plasma levels of protein carbonyl groups, was significantly associated with a 60% increased risk of breast cancer.7 However, in contrast to the present study, bloods were collected on average 3 months after diagnosis and thus could have been impacted by disease. Previous smaller studies have provided conflicting evidence on the association between protein oxidation and cancer risk, with positive results for Hodgkin’s lymphoma9 and bladder cancer,10 but not for lung11 or brain12 cancer. None of these studies were prospective.
While aging is accompanied by increasing levels of oxidative damage, including protein oxidation (reviewed in 13), no associations with age were observed in our study, perhaps due to the narrow age range of our participants. Significantly higher levels of oxidized proteins in smokers than in nonsmokers have been observed11;14 but we found no association between serum protein carbonyl levels and smoking status. Conflicting data have been observed for an association with fruit and vegetable intake.7;15–18 The lack of an association between these factors believed to be associated with increased oxidative stress and serum oxidized protein concentrations suggests that this measure may not be sensitive to environmental factors that increase oxidative stress.
In summary, in this large study using bloods collected before diagnosis, we found no association between serum protein carbonyl levels and prostate cancer risk. Among controls, oxidized protein levels were not significantly associated with factors thought to be associated with oxidative stress. It is possible that serum levels of oxidized proteins do not accurately reflect oxidative damage in the prostate, where there may be a higher inflammatory environment; studies examining prostate tissue for oxidative damage may help clarify the role of oxidative stress in prostate cancer etiology.
Grant support: Funded in part by grants P01 CA108964, CA37429, P30 ES009089, R03 CA117490 and P30 CA013696 from the National Cancer Institute and the National Institute of Environmental Health Sciences.